FMP
Lexaria Bioscience Corp.
LEXX
NASDAQ
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
1.19 USD
-0.04 (-3.36%)
2025 Q2
2025 Q1
2024 Q4
2024 Q3
174k
183.92k
84k
84k
0
2.72k
0
0
174k
181.2k
84k
84k
2.93M
2.87M
2.29M
1.83M
1.69M
1.95M
967.21k
573.09k
1.24M
918.69k
1.32M
1.25M
0
0
0
0
1.24M
918.69k
1.32M
1.25M
0
0
0
0
-2.75M
-2.69M
-2.2M
-1.74M
37.8k
-12.99k
16.49k
-41.39k
-2.71M
-2.7M
-2.19M
-1.78M
3.76k
0
0
0
-2.71M
-2.7M
-2.18M
-1.78M
-0.15
-0.16
-0.17
-0.13
-0.15
-0.16
-0.17
-0.13
17.51M
16.67M
13.12M
13.86M
17.51M
16.67M
13.12M
13.86M
-2.75M
-2.69M
-2.2M
-1.73M
2025 Q2
2025 Q1
2024 Q4
2024 Q3
-54.26M
-51.56M
-49.37M
-47.59M
-2.71M
-2.7M
-2.18M
-1.78M
0
0
0
0
0
0
0
0
-56.98M
-54.26M
-51.56M
-49.37M
-2.71M
-2.7M
-2.18M
-1.78M
2025 Q2
2025 Q1
2024 Q4
2024 Q3
358.33k
398.65k
389.55k
362.61k
0
0
-7.76k
15.07k
0
0
-69.59k
-22k
358.33k
398.65k
466.9k
369.53k
2025 Q2
2025 Q1
2024 Q4
2024 Q3
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.